AdipoPharma

Executive Summary

AdipoPharma is a French preclinical biotech founded in 2017 and based in Lyon, developing first-in-class therapies targeting the adipocyte to treat metabolic diseases, primarily insulin resistance and type 2 diabetes. Its lead asset, PATAS, is a novel insulin sensitizer derived from over a decade of genetic research into adipocyte function in Alström syndrome. The company aims to address the root cause of metabolic dysfunction by improving adipocyte health, potentially offering a differentiated approach compared to existing therapies. As a preclinical-stage company, AdipoPharma has not yet disclosed funding rounds or valuation, suggesting it is likely still in early research or seed-stage development. The company's next milestones are expected to include completion of key preclinical efficacy and toxicology studies, which will be critical for advancing PATAS toward IND-enabling activities and attracting strategic partnerships or Series A financing. Given the early stage, significant execution risk remains, but the scientific rationale and novel mechanism provide a compelling basis for further investment and development.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for PATAS in animal models25% success
• TBDSeries A financing or non-dilutive grant award30% success
• TBDPartnership with pharmaceutical company for metabolic disease collaboration15% success